Bevacizumab
| CAS No. | 216974-75-3 | Cat. No. | BCP07998 |
| Name | Bevacizumab | ||
| Synonyms | Avastin;Anti-vegf monoclonal antibody;Rhumab-vegf; | ||
| Formula | C6638H10160N1720O2108S44 | M. Wt | 149196.82 |
| Description | Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first available angiogenesis inhibitor in the United States. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | VEGFR | ||
|
The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
Publications Citing of Biochempartner's Bevacizumab(CAS:216974-75-3) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.